Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lestaurtinib with Chemotherapy in Young Patients with Relapsed/Refractory FLT3-mutant AML
NCT00469859Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lestaurtinib in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Dose-limiting Toxicity at 28 days and Inhibition of FLT3 Phosphorylation at Day 28. Started Jun 2007; status: completed.
02
Drugs
lestaurtinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00469859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469859.